A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1

Summary

The primary purpose of this study is to evaluate the efficacy of single oral doses of E2086 compared to placebo in the treatment of excessive daytime sleepiness (EDS) as assessed by the Maintenance of Wakefulness Test (MWT) in adult participants with narcolepsy type 1 (NT1).

Timeline

Start

2024-06-20

Primary completion

2025-03-17

Completion

2025-03-17

Outcome

Met primary endpoint

release “As evaluated by MWT, all doses of E2086 demonstrated statistically significant longer sleep latencies *3” eisai.com ↗

Drugs

Indications